Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Naokazu Watari"'
Autor:
Naokazu Watari, Kakuhiro Yamaguchi, Hiroaki Terada, Kosuke Hamai, Ken Masuda, Yoshifumi Nishimura, Shinjiro Sakamoto, Takeshi Masuda, Yasushi Horimasu, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto, Hiroyasu Shoda, Nobuhisa Ishikawa, Kazunori Fujitaka, Kozue Miyazaki, Yoshihiro Miyata, Hironobu Hamada, Kazuo Awai, Noboru Hattori
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mesenchymal-epithelial transition exon14 (METex14) skipping is one of the therapeutic driver oncogene mutations in non-small cell lung cancer (NSCLC), and can be treated with tepotinib and capmatinib. There is only one report on c
Externí odkaz:
https://doaj.org/article/bece7498093044a7bbb19690580de0ce
Autor:
Naokazu Watari, Kakuhiro Yamaguchi, Takeshi Masuda, Noriaki Ito, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Noboru Hattori
Publikováno v:
Thoracic Cancer, Vol 12, Iss 21, Pp 2956-2960 (2021)
Abstract The IMpower133 regimen, composed of atezolizumab/etoposide (VP‐16)/carboplatin (CBDCA), is the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC). However, the safety and efficacy of triplet therapy in
Externí odkaz:
https://doaj.org/article/f8c7eca257654325ae0d7876e0201ef5